Illumina Q2 2026 revenue growth accelerates on rising clinical demand, strong NovaSeq X placements, company says
ILMN•Q2 revenue and demand trends
- Illumina posted Q2 2026 revenue of $1.16 billion, up 9.5%, driven by rising clinical demand and higher NovaSeq X consumables pull-through.
- Rest-of-world organic revenue grew 8.1%, beating guidance; sequencing gigabase output on connected high- and mid-throughput systems rose over 30%.
- NovaSeq X demand stayed elevated with over 95 placements; instrument revenue rose 31% to $125 million, supported by supply improvements.
- Non-GAAP gross margin was 68.2% despite higher freight and memory costs; non-GAAP EPS was $1.31, up 10%.
- Full-year guidance increased to $4.60-$4.64 billion revenue, rest-of-world organic growth above 5%, EPS of $5.30-$5.40 on mid-teens clinical growth.
